Additional funding for research and development costs incurred

No definition available.

Name:	adxn_AdditionalFundingForResearchAndDevelopmentCostsIncurred
Namespace Prefix:	adxn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Annual funding for research and development costs incurred

+ References

No definition available.

+ Details

Name:	adxn_AnnualFundingForResearchAndDevelopmentCostsIncurred
Namespace Prefix:	adxn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Increment period for extension of research term

+ References

No definition available.

+ Details

Name:	adxn_IncrementPeriodForExtensionOfResearchTerm
Namespace Prefix:	adxn_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Initial research term

+ References

No definition available.

+ Details

Name:	adxn_InitialResearchTerm
Namespace Prefix:	adxn_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of distinct material promises and performance obligations

+ References

No definition available.

+ Details

Name:	adxn_NumberOfDistinctMaterialPromisesAndPerformanceObligations
Namespace Prefix:	adxn_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of newly identified components selected

+ References

No definition available.

+ Details

Name:	adxn_NumberOfNewlyIdentifiedComponentsSelected
Namespace Prefix:	adxn_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Variable consideration allocated to contract

+ References

No definition available.

+ Details

Name:	adxn_VariableConsiderationAllocatedToContract
Namespace Prefix:	adxn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The amount of an entity’s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 15
-IssueDate 2019-01-01
-Paragraph 105
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2019-en-r&anchor=para_105&doctype=Standard
-URIDate 2019-03-27

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 15
-IssueDate 2019-01-01
-Paragraph 116
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2019-en-r&anchor=para_116_a&doctype=Standard
-URIDate 2019-03-27

+ Details

Name:	ifrs-full_ContractLiabilities
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.

+ References

No definition available.

+ Details

Name:	ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity’s ordinary activities in exchange for consideration.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 15
-IssueDate 2019-01-01
-Paragraph 113
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2019-en-r&anchor=para_113_a&doctype=Standard
-URIDate 2019-03-27

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 15
-IssueDate 2019-01-01
-Paragraph 114
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2019-en-r&anchor=para_114&doctype=Standard
-URIDate 2019-03-27

+ Details

Name:	ifrs-full_RevenueFromContractsWithCustomers
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	ifrs-full_CounterpartiesAxis=adxn_IndiviorPlcMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_ProductsAndServicesAxis=adxn_RightsGrantedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_ProductsAndServicesAxis=adxn_IfrsResearchMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_ProductsAndServicesAxis=adxn_AchievementOfPreSpecifiedMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=adxn_IndiviorPlcMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_CounterpartiesAxis=adxn_JanssenPharmaceuticalsInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_ProductsAndServicesAxis=adxn_DevelopmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Revenue from contract with customer (Details) € in Millions, $ in Millions				1 Months Ended	2 Months Ended	12 Months Ended
	Dec. 20, 2019 USD ($)	Oct. 07, 2019 USD ($)	Jan. 02, 2018 USD ($) item	Jan. 31, 2018 USD ($)	Dec. 20, 2019 USD ($)	Dec. 31, 2019 CHF (SFr)	Dec. 31, 2018 USD ($)	Dec. 31, 2018 CHF (SFr)	Dec. 31, 2004 EUR (€)
Revenue from contract with customer
Revenue from contracts with customers						SFr 2,762,830		SFr 6,043,855
Indivior PLC
Revenue from contract with customer
Number of distinct material promises and performance obligations \| item			2
Indivior PLC \| Rights granted
Revenue from contract with customer
Revenue from contracts with customers				$ 5.0			$ 5.0	4,900,000
Indivior PLC \| Research
Revenue from contract with customer
Revenue from contracts with customers						2,800,000		1,200,000
Initial research term			2 years
Increment period for extension of research term			12 months
Number of newly identified components selected \| item			1
Additional funding for research and development costs incurred \| $	$ 0.8	$ 0.8			$ 1.6
Contract liabilities						900,000		200,000
Indivior PLC \| Research \| Minimum
Revenue from contract with customer
Annual funding for research and development costs incurred \| $			$ 2.0
Indivior PLC \| Achievement of pre-specified milestones
Revenue from contract with customer
Variable consideration allocated to contract \| $			$ 330.0
Indivior PLC \| Indivior PLC \| Research
Revenue from contract with customer
Number of newly identified components selected \| item			1
Janssen Pharmaceuticals Inc. \| Development
Revenue from contract with customer
Revenue from contracts with customers						SFr 0		SFr 0
Janssen Pharmaceuticals Inc. \| Development \| Maximum
Revenue from contract with customer
Variable consideration allocated to contract \| €									€ 109